Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

Part of paid clinical trials in Palo Alto, California.

Sponsor
Stanford University
Study ID
NCT07594431
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Metastases
  • Metastatic Cancer

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LATTICE Radiotherapy — RADIATION
    5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
  • Standard radiotherapy — RADIATION
    Standard radiotherapy delivered to 25 Gy in 5 fractions.

Study Details

Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)

Key Dates

First listed
May 18, 2026
Start date
Aug 28, 2026
Status verified
Sep 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LATTICE Radiotherapy
    Participants receive 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
  • Active Comparator: Standard Radiotherapy
    Participants receive standard radiotherapy (25 Gy in 5 fractions)

Primary Outcome Measure

Percent Tumor Volume Reduction Following Radiotherapy [ Time Frame: 90 +/- 20 days following radiotherapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityPalo AltoCalifornia94304
Jamie Wong
[email protected]
650-497-4354
Camellia Djebroun
[email protected]
650-736-5564
Michael Gensheimer, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By research site
Stanford University· Palo Alto, CA

Related Studies